Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761282 | 1.00 | PTGER4 (0.40) | PTGER4PTGER2SCN9ANAAAACACB | |
| SCHEMBL6760380 | 0.87 | KCNH2 (0.40) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6760377 | 0.87 | KCNH2 (0.40) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6761301 | 0.83 | HCRTR2 (0.40) | SCN9ANAAAGRIN1GRIN2BGPR119 | |
| SCHEMBL6761297 | 0.83 | HCRTR2 (0.40) | SCN9ANAAAGRIN1GRIN2BGPR119 | |
| SCHEMBL6763114 | 0.81 | CCR1 (0.40) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6763101 | 0.81 | CCR1 (0.40) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6763119 | 0.80 | GPR119 (0.37) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6763123 | 0.80 | GPR119 (0.37) | PTGER4PTGER2SCN9ANAAAGRIN1 | |
| SCHEMBL6765181 | 0.79 | NPC1 (0.47) | NAAAEPHX2HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | claimed |
| US-20040063688-A1 | Novel piperidine derivatives | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063688-A1 | Novel piperidine derivatives | CCR1, CCR3, CCR2 | PTGER4 831/4885PTGER2 819/4885SCN9A 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.